Stem cell trial aims to regrow lungs in COPD patients

NCT ID NCT07355868

Recruiting now Disease control Sponsor: Regend Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests REGEND007, a stem cell therapy made from airway cells, in 12 people with COPD. The cells are given by IV infusion in increasing doses to see if they are safe and can help repair lung damage. The study is still recruiting and focuses on safety first.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: REGEND007 (airway basal layer stem cells)
What this could lead to: If it works, this could point toward a treatment that repairs lung tissue and improves breathing in COPD patients.
What could go wrong: This is a very early, small trial (12 people) focused on safety. It may not show clear benefit, and stem cell therapies carry risks like immune reactions or uncertain long-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

Contacts and locations

Locations

The Fourth Hospital of Zhejiang University School of Medicine
RECRUITING

Yiwu, Zhejiang, 322000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.